pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.

Diabetes 52

Diabetes Immunity Immunization 52

Express Pharma

SEPTEMBER 12, 2023

tumor formation, immune reactions, and therapy failure). tumor formation, immune reactions, and therapy failure). HepaStem is projected to hit the US market in Q1 2027, while BioVie’s BIV201 is anticipated to be marketed in Q4 2028.

Diabetes 111

Diabetes Immunity Immunization 111

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Diabetes Therapy. The Business Research Company.

Biosimilars 87

Biosimilars Diabetes Immunity Immunization 87